Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Mattson Financial Services LLC

Mattson Financial Services LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 19,636 shares of the medical equipment provider’s stock after acquiring an additional 1,616 shares during the quarter. Mattson Financial Services LLC’s holdings in Zimmer Biomet were worth $2,222,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Garde Capital Inc. acquired a new stake in Zimmer Biomet during the first quarter worth about $29,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $30,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the first quarter valued at about $30,000. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the first quarter valued at about $30,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Zimmer Biomet during the first quarter valued at about $35,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Trading Down 1.5%

Shares of ZBH stock opened at $102.33 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The stock has a market capitalization of $20.27 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.68. The company has a 50 day moving average price of $99.06 and a 200 day moving average price of $99.63. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The firm had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ZBH. Raymond James Financial lifted their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Evercore ISI dropped their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research report on Tuesday, July 8th. UBS Group lifted their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Finally, Royal Bank Of Canada lifted their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $111.00.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.